Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541889 · ClinicalTrials.gov registry record · Phase 1
REVEAL Biomarkers of Engraftment After Alternative Donor HSCT
A Phase 1 study of Primary Graft Failure, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 4
- Study locations
NCT03541889: Recruiting Phase 1 study of Primary Graft Failure, sponsored by University of Oklahoma.
NCT03541889 is a Phase 1 study of Primary Graft Failure that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03541889, a Phase 1 study of Primary Graft Failure, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples to investigate whether the cells are growing well.
Primary Outcome
To calculate if SUV \> 1.2 identifies subclinical engraftment using FLT PET/CT imaging for recipients of cord and haplo-HSCT who have not engrafted within 24 days of HSCT.
Conditions Studied
Interventions
- DRUG FLT imaging and TK1 blood measurements
Study Locations (4)
Georgia
- Emory University - Atlanta
Michigan
- University of Michigan - Ann Arbor
Ohio
- University Hospital of Cleveland UH Seidman Cancer Center - Cleveland
Oklahoma
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
What NCT03541889 shows while recruiting
NCT03541889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Primary Graft Failure appearing as the primary indexed condition, and to 1 intervention - of which FLT imaging and TK1 blood measurements is the first listed.
NCT03541889 reports a single indexed study location in Georgia, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT03541889 about?
NCT03541889 is a clinical study titled "REVEAL Biomarkers of Engraftment After Alternative Donor HSCT". The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples...
What is the current status of trial NCT03541889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-02-05. Estimated completion is 2027-11.
What conditions does trial NCT03541889 study?
This clinical trial studies the following conditions: Primary Graft Failure.
What interventions are being tested in trial NCT03541889?
The interventions under investigation include: FLT imaging and TK1 blood measurements (DRUG).
Who is sponsoring clinical trial NCT03541889?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03541889 being conducted?
This trial has 4 study locations across Georgia, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Graft Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03541889's enrollment target sits among peer trials
56 903rd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI